Difference between revisions of "Camrelizumab (AiRuiKa)"
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
m |
||
Line 12: | Line 12: | ||
*[[Non-small cell lung cancer, squamous]] | *[[Non-small cell lung cancer, squamous]] | ||
+ | ==History of changes in NMPA indication== | ||
+ | *2019-05-29: Initial approval | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' HR-301210, SHR-1210 | *'''Code names:''' HR-301210, SHR-1210 | ||
− | *'''Brand | + | *'''Generic name:''' carrelizumab |
+ | *'''Brand names:''' AiRuiKa, Erica | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Line 26: | Line 29: | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
− | [[Category:NMPA approved | + | [[Category:NMPA approved in 2019]] |
Revision as of 02:19, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Toxicity management
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Hepatocellular carcinoma
- Classical Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, squamous
History of changes in NMPA indication
- 2019-05-29: Initial approval
Also known as
- Code names: HR-301210, SHR-1210
- Generic name: carrelizumab
- Brand names: AiRuiKa, Erica